Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.
Frontier Medicines Announces Series C Funding to Advance Development of Next Generation KRAS Blocker
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours